FDA Classifies Phase-Changing Fiducial Marker for Radiation Therapy into Class II

Summary

The FDA has classified the phase-changing fiducial marker for radiation therapy into Class II, a move aimed at ensuring the device's safety and effectiveness while reducing regulatory burdens, ultimately enhancing patients' access to innovative devices.